The Susan G. Komen Breast Cancer Foundation reported a 22 percent decline in contributions in fiscal 2013—totalling over $77 million—in recent financial statements.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
